Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun 17;1(1):48-54.
doi: 10.3109/21556660.2012.703630. eCollection 2012.

Trial of pranlukast inhibitory effect for cedar exposure using an OHIO chamber

Shuichiro Endo  1 , Minoru Gotoh  2 , Kimihiro Okubo  3 , Kazuhiro Hashiguchi  4 , Hidenori Suzuki  5 , Keisuke Masuyama  1
Affiliations

Trial of pranlukast inhibitory effect for cedar exposure using an OHIO chamber

Shuichiro Endo et al. J Drug Assess. .

Abstract

Objective: In practical guidelines for management of allergic rhinitis in Japan, pranlukast is a leukotriene receptor antagonist recommended for the treatment of pollinosis. However, the effect of pranlukast on nasal symptoms for cedar pollinosis has not been thoroughly investigated. The aim of this study is to examine this effect in a double-blind controlled crossover study using a pollen challenge chamber (the OHIO Chamber) developed in Japan.

Research design and methods: A total of 39 patients with cedar pollinosis were targeted. The subjects were exposed to a specific amount of cedar pollen (8000/m(3)) in the OHIO Chamber during the non-cedar pollen season. Efficacy of pranlukast for the treatment of artificially induced nasal symptoms was compared with that of a placebo using the crossover method. Pranlukast was administered orally for 3 days, after dinner on the day before cedar pollen exposure, after breakfast and after dinner on the day of cedar pollen exposure, and after breakfast on the following day. Pollen testing was carried out twice, with a 1-week wash-out interval.

Clinical trial registration: The University Hospital Medical Information Network in Japan (UMIN), number UMIN000001282.

Main outcome measures: The effect of pranlukast was evaluated using self-rating of nasal symptoms by the subjects.

Results: All 39 subjects demonstrated a positive skin reaction to cedar pollen by a positive CAP-RAST score (class 2 or higher) within the last 3 years, and experienced aggravated congestion during the cedar pollen season for more than 2 years. Nasal congestion was inhibited significantly in the pranlukast group compared to the placebo group during cedar pollen exposure. Furthermore, pranlukast significantly inhibited nasal congestion compared to the placebo on the day after exposure and on the following day.

Conclusions: The effect of pranlukast on cedar pollinosis indicates immediate action, and such an effect could take place continuously after cedar pollen exposure. These results demonstrate that pranlukast is effective for the relief of congestion due to pollinosis.

Keywords: Cedar pollinosis; Crossover trial; Nasal symptoms; OHIO chamber; Pranlukast.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Study schedule. The study periods consisted of visit 1, washout and visit 2. Eligible subjects were enrolled in the treatment period and randomized to receive pranlukast or placebo for 3 days (visit 1) followed by a washout period of 7 days, and then crossed over to the other treatment period for 3 days (visit 2). Subjects were exposed to cedar pollen in the OHIO chamber for 3 hours on the second day of each treatment period.
Figure 2.
Figure 2.
Changes in sneezing score.
Figure 3.
Figure 3.
Changes in nasal discharge score.
Figure 4.
Figure 4.
Changes in nasal congestion score.
Figure 5.
Figure 5.
Changes in total nasal symptom score.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Worldwide variation in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis and atopic eczema: ISAAC The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998;351:1225-32 - PubMed
    1. Okuda M. Epidemiology of Japanese cedar pollinosis throughout Japan. Ann Allergy Asthma Immunol 2003;91:288-96 - PubMed
    1. Sakashita M, Hirota T, Harada M, et al. Prevalence of allergic rhinitis and sensitization to common aeroallergens in a Japanese population. Int Arch Allergy Immunol 2010;151:255-61 - PubMed
    1. Yonetomi Y, Fujita M, Nakagawa N, et al. Preclinical pharmacology of pranlukast. Clin Exp Allergy Rev 2001;1:210-17
    1. Tamaoki J, Kondo M, Sakai N, et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. Am J Respir Crit Care Med 1997;155:1235-40 - PubMed

LinkOut - more resources